dr. farago on eligibility criteria for frontline immunotherapy in sclc
Published 5 years ago • 113 plays • Length 1:41Download video MP4
Download video MP3
Similar videos
-
2:46
dr. farago on frontline immunotherapy versus maintenance immunotherapy in sclc
-
1:09
dr. farago on opportunities to investigate biomarkers for small cell lung cancer
-
2:50
dr. farago on effectiveness of single-agent lurbinectedin in sclc
-
0:35
dr. farago on the fda approval of pembrolizumab for lower pd-1 cutoff nsclc
-
0:48
immunotherapy for patients with small-cell lung cancer
-
2:54
current frontline management of small cell lung cancer
-
4:37
frontline therapy approaches for small cell lung cancer
-
1:05
dr. kim on role of frontline immunotherapy in advanced hcc
-
1:36
dr. costin on frontline immunotherapy for patients with nsclc
-
1:48
dr. mark kris on immunotherapy and frontline options for patients with nsclc
-
1:56
dr. jahanzeb on eligibility criteria for immunotherapy trials in nsclc
-
3:12
post-immunotherapy & frontline treatments for advanced nsclc
-
2:09
dr. perez-soler on immunotherapy advances in sclc
-
1:15
dr. langer on the impact of frontline immunotherapy in lung cancer
-
2:30
dr. lopes on the keynote-042 results of frontline pembrolizumab in nsclc
-
1:40
dr. piotrowska on eligibility criteria for osimertinib in lung cancer treatment
-
1:45
dr. farago on combination of olaparib and temozolomide in small cell lung cancer
-
1:36
dr. rudin on expansion of immunotherapy in lung cancer
-
0:36
dr. camidge on the fda approval of pembrolizumab for squamous nsclc